Xanthine derivative, production and use thereof as a medicament

Details for Australian Patent Application No. 2002234640 (hide)

Owner Boehringer Ingelheim Pharma GmbH & Co. KG

Inventors Himmelsbach, Frank; Maier, Roland; Eckjardt, Matthias; Lotz, Ralf; Mark, Michael; Langkopf, Elke

Agent Davies Collison Cave

Pub. Number AU-B-2002234640

PCT Pub. Number WO2002/068420

Priority 101 40 345.3 17.08.01 DE; 101 09 021.8 24.02.01 DE; 102 03 486.9 30.01.02 DE; 101 17 803.4 10.04.01 DE

Filing date 21 February 2002

Wipo publication date 12 September 2002

Acceptance publication date 8 October 2009

International Classifications

C07D 473/04 (2006.01) Heterocyclic compounds containing purine ring systems

A61K 31/522 (2006.01)

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61K 31/551 (2006.01) - having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 5/00 (2006.01) Drugs for disorders of the endocrine system

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 19/10 (2006.01) Drugs for skeletal disorders

A61P 37/02 (2006.01) Drugs for immunological or allergic disorders

C07D 473/06 (2006.01) Heterocyclic compounds containing purine ring systems

C07D 473/08 (2006.01) Heterocyclic compounds containing purine ring systems

C07D 473/10 (2006.01) Heterocyclic compounds containing purine ring systems

C07D 473/12 (2006.01) Heterocyclic compounds containing purine ring systems

Event Publications

6 March 2003 Application Open to Public Inspection

  Published as AU-B-2002234640

18 October 2007 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

1 November 2007 Corrigenda

  Applications Lapsed, Refused or Withdrawn, Patents Ceased or Expired - 2002 Delete all reference to Application No. 2002234640

8 October 2009 Application Accepted

  Published as AU-B-2002234640

5 November 2009 Corrigenda

  Applications Accepted - Name Index Under the name Boehringer Ingelheim Pharma GmbH & Co. KG, Application No. 2002234640, under INID (72) correct the co-inventor to Eckhardt, Matthias

4 February 2010 Standard Patent Sealed

2 February 2012 Extension of Term of Standard Patents

  Boehringer Ingelheim Pharma GmbH & Co. KG The earliest first regulatory approval date provided by the patentee 01 Nov 2011 For the goods TRAJENTA Linagliptin Address for service in Australia: Davies Collison Cave 1 Nicholson Street Melbourne VIC 3000

7 June 2012 Extension granted

  Boehringer Ingelheim Pharma GmbH & Co. KG The earliest first regulatory approval date provided by the patentee 01 Nov 2011 For the goods TRAJENTA Linagliptin Extension of Term of patent pursuant to Section 77 expires on 01 Nov 2026

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002234641-METHOD FOR ANALYTICALLY EXAMINING A BEER SAMPLE

2002234639-Dispenser with effervescent beverage product